Abstract 355P
Background
In Australia, 58% of cancer diagnoses and 76% of cancer mortality is in patients aged >65. Comorbidity increases with age, and both factors affect cancer treatment choices, initiation and outcomes, and health related quality of life (HRQoL). Rurality also impacts these experiences, however despite emerging evidence, rural geriatric oncology populations are underrepresented in available studies. This study therefore aims to determine the prevalence of physical comorbidities among this cohort, and to study the relationship between comorbidity, rurality, treatment process and outcomes, and HRQoL.
Methods
The study includes patients aged >65, with any solid tumour diagnosis, attending a regional cancer centre. Quantitative data was obtained using validated tools to examine HRQoL, comorbidities, and clinical parameters, with analysis of predictor variables to quantity association with comorbidity and rurality. Qualitative data was obtained via focus groups with patient, caregiver and health professional cohorts, with thematic analysis undertaken using iterative coding.
Results
Qualitative data highlighted factors influencing diagnosis and treatment, including: difficulty/cost of travel; and other impacts of living in a regional location. Diagnosis delay/complication and emotional aspects were identified as key to cancer experiences, and in HRQoL. Preliminary analysis of quantitative data collected to date (n=110) complements this, with 57% of patients classified as living in outer regional Australia, and 24% as inner regional. Around 30% had at least one comorbidity. A significant relationship does appear between rurality, comorbidities, and HRQoL. The relationship with treatment outcomes is less clear.
Conclusions
Preliminary analysis identifies several key challenges to treatment commencement and completion, including financial, logistical and emotional issues. Statistical analysis further indicates that both rurality and comorbidities may negatively impact HRQoL, and treatment commencement/completion. Data collection and analysis is ongoing to end 2020.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hunter New England Local Health District - Tamworth Rural Referral Hospital.
Funding
Tamworth Hospital, Hunter New England Local Health District.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
297P - Factors affecting duration of admission in the palliative medicine ward of a tertiary cancer hospital: A pilot, investigator initiated, review of services
Presenter: Rahul D. Arora
Session: e-Poster Display Session
298P - Abandonment of treatment in teenagers and young adults with cancer: A multi institutional survey
Presenter: B S Ankit
Session: e-Poster Display Session
304P - Identification of nine lncRNAs signature for predicting survival benefit of melanoma patients treated with immune checkpoint inhibitors
Presenter: Jian-Guo Zhou
Session: e-Poster Display Session
305P - Novel co-occurring genomic alterations associated with prediction and prognosis in lung adenocarcinoma
Presenter: Xin Zhao
Session: e-Poster Display Session
306P - Detection of anaplastic lymphoma kinase (ALK) mutations using circulating tumour DNA (ctDNA) in advanced non-squamous non-small cell lung cancer (non-Sq-NSCLC) in Asia
Presenter: Kirsty Lee
Session: e-Poster Display Session
307P - Development of circulating free DNA methylation markers for thyroid nodule diagnostics
Presenter: Shuibing Hong
Session: e-Poster Display Session
308P - The genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumour DNA (ctDNA) in clinical practice
Presenter: Byoung Cho
Session: e-Poster Display Session
309P - Improved diagnostic accuracy in MRI breast lesions using a classification system and multilayer perceptron neural network
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
310P - Genomic biomarker detection in East Asian clinical practice using circulating tumour DNA (ctDNA) from patients with gastrointestinal (GI) tract cancers
Presenter: Sadakatsu Ikeda
Session: e-Poster Display Session
311P - Effect of chemotherapy on fatty liver occurrence in breast and gastrointestinal cancer patients
Presenter: Seyed Alireza Javadinia
Session: e-Poster Display Session